Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Letter
  • Published:

Perindopril and candesartan comparative efficacy and safety in type II diabetic hypertensive patients

Journal of Human Hypertension volume 17, pages 433–435 (2003)Cite this article

Dear Sir,

Cardiovascular and cerebrovascular disease risks are almost doubled when the hypertensive patient is also affected by diabetes mellitus. Lowering of blood pressure markedly decreases the rate of cardiovascular events and renal deterioration in these patients.1 Recent comparative studies in diabetes suggest that, for the prevention of cardiovascular events, angiotensin converting (ACE) inhibitors may be superior to alternative antihypertensive agents, independently of their antihypertensive effect.2 Compared to ACE inhibitors, angiotensin receptor blockers (ARBs) offer more complete and pharmacologically desirable blockade of the renin–angiotensin system, and they are free from the adverse effect of cough observed with the administration of ACE inhibitors.3 Metabolic abnormalities as insulin resistance, impairment lipid profile, and decreased fibrinolytic activity can be improved by ACE inhibitors.2 ARBs have been shown to retard the progression of albuminuria and the development and progression of nephropathy,4 but there are few data of the ARBs action on metabolic parameters, especially in comparison with ACE inhibitors, in diabetic subjects.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Arauz-Pacheco C, Parrott MA, Raskin P . The treatment of hypertension in adult patients with diabetes. Diabetes Care 2002; 25: 134–147.

    Article  Google Scholar 

  2. Pahor M, Psaty BM, Furberg CD . Treatment of hypertensive patients with diabetes. Lancet 1998; 351: 689–690.

    Article  CAS  Google Scholar 

  3. Pylypchuk GB . ACE inhibitor—versus angiotensin II blocker—induced cough and angioedema. Ann Pharmacother 1998; 32: 1060–1066.

    Article  CAS  Google Scholar 

  4. Gradman AH . AT(1)-receptor blockers: differences that matter. J Hum Hypertens 2002; 16 (Suppl. 3): S9–S16.

    Article  CAS  Google Scholar 

  5. The Expert Committeee on the diagnosis and classification of diabetes mellitus. Report of the Expert Committeee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003; 26 (Suppl. 1): 5–20.

    Google Scholar 

  6. Fogari R et al. Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetic patients. Am J Hypertens 2002; 15: 316–320.

    Article  CAS  Google Scholar 

  7. Bonora E et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity. 2000; 23: 57–63.

  8. Trenkwalder P, Lehtovirta M, Dahl K . Long-term treatment with candesartan cilexetil does not affect glucose homeostasis or serum lipid profile in mild hypertensives with type II diabetes. J Hum Hypertens 1997; 11 (Suppl. 2): S81–S83.

    CAS  PubMed  Google Scholar 

  9. Higashiura K, Ura N, Miyazaki Y, Shimamoto K . Effect of an angiotensin II receptor antagonist, candesartan, on insulin resistance and pressor mechanisms in essential hypertension. J Hum Hypertens 1999; 13 (Suppl. 1): S71–S74.

    Article  CAS  Google Scholar 

  10. Derosa G et al. Effects of fosinopril on blood pressure, lipid profile, and lipoprotein (a) levels in normotensive patients with type 2 diabetes and microalbuminuria: an open-label, uncontrolled study. Curr Ther Res Clin Exp 2002; 63: 216–226.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine and Therapeutics University of Pavia, Pavia, Italy

    G Derosa, A Mugellini, L Ciccarelli & R Fogari

  2. Department of Clinical Medicine and Applied Biotechnolgy ‘D Campanacci’, University of Bologna, Bologna, Italy

    A F G Cicero

Authors
  1. G Derosa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A F G Cicero
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Mugellini
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L Ciccarelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R Fogari
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G Derosa.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Derosa, G., Cicero, A., Mugellini, A. et al. Perindopril and candesartan comparative efficacy and safety in type II diabetic hypertensive patients. J Hum Hypertens 17, 433–435 (2003). https://doi.org/10.1038/sj.jhh.1001572

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.jhh.1001572

Search

Advanced search

Quick links